JP2024529430A - がんの処置における使用のための１－（４－｛［４－（ジメチルアミノ）ピペリジン－１－イル］カルボニル｝フェニル）－３－［４－（４，６－ジモルホリン－４－イル－１，３，５－トリアジン－２－イル）フェニル］尿素（ゲダトリシブ）およびその組合せ - Google Patents

がんの処置における使用のための１－（４－｛［４－（ジメチルアミノ）ピペリジン－１－イル］カルボニル｝フェニル）－３－［４－（４，６－ジモルホリン－４－イル－１，３，５－トリアジン－２－イル）フェニル］尿素（ゲダトリシブ）およびその組合せ Download PDF

Info

Publication number
JP2024529430A
JP2024529430A JP2024504503A JP2024504503A JP2024529430A JP 2024529430 A JP2024529430 A JP 2024529430A JP 2024504503 A JP2024504503 A JP 2024504503A JP 2024504503 A JP2024504503 A JP 2024504503A JP 2024529430 A JP2024529430 A JP 2024529430A
Authority
JP
Japan
Prior art keywords
cancer
administration
cycles
week
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024504503A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024529430A5 (https=
Inventor
ブライアン フランシス サリバン，
ランス ギャビン レイン，
Original Assignee
セルキュイティー インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セルキュイティー インコーポレイテッド filed Critical セルキュイティー インコーポレイテッド
Publication of JP2024529430A publication Critical patent/JP2024529430A/ja
Publication of JP2024529430A5 publication Critical patent/JP2024529430A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024504503A 2021-07-26 2022-07-25 がんの処置における使用のための１－（４－｛［４－（ジメチルアミノ）ピペリジン－１－イル］カルボニル｝フェニル）－３－［４－（４，６－ジモルホリン－４－イル－１，３，５－トリアジン－２－イル）フェニル］尿素（ゲダトリシブ）およびその組合せ Pending JP2024529430A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163225707P 2021-07-26 2021-07-26
US63/225,707 2021-07-26
US202163285327P 2021-12-02 2021-12-02
US63/285,327 2021-12-02
PCT/US2022/038188 WO2023009438A1 (en) 2021-07-26 2022-07-25 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea (gedatolisib) and its combinations for use in the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2024529430A true JP2024529430A (ja) 2024-08-06
JP2024529430A5 JP2024529430A5 (https=) 2025-07-24

Family

ID=82932627

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024504503A Pending JP2024529430A (ja) 2021-07-26 2022-07-25 がんの処置における使用のための１－（４－｛［４－（ジメチルアミノ）ピペリジン－１－イル］カルボニル｝フェニル）－３－［４－（４，６－ジモルホリン－４－イル－１，３，５－トリアジン－２－イル）フェニル］尿素（ゲダトリシブ）およびその組合せ

Country Status (11)

Country Link
US (2) US12350276B2 (https=)
EP (1) EP4376848A1 (https=)
JP (1) JP2024529430A (https=)
KR (1) KR20240040768A (https=)
AU (2) AU2022320615B2 (https=)
CA (1) CA3227191A1 (https=)
CL (1) CL2024000208A1 (https=)
IL (1) IL310243A (https=)
MX (1) MX2024001266A (https=)
TW (1) TW202320795A (https=)
WO (1) WO2023009438A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025049962A1 (en) * 2023-08-31 2025-03-06 Aadi Bioscience, Inc. Combination cancer treatments with a composition comprising an mtor pathway inhibitor
US20260053814A1 (en) * 2024-08-21 2026-02-26 Celcuity Inc. Treatment regimens for gedatolisib in hormonally-driven disorders

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998402A (en) 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
MXPA04005939A (es) 2002-01-22 2005-01-25 Warner Lambert Co 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas.
GB0327380D0 (en) 2003-11-25 2003-12-31 Cyclacel Ltd Method
EP1846408B1 (en) 2005-01-14 2013-03-20 Janssen Pharmaceutica NV 5-membered annelated heterocyclic pyrimidines as kinase inhibitors
LT2294072T (lt) 2008-05-23 2017-06-12 Wyeth Llc Triazino junginiai, kaip p13 kinazės ir mtor inhibitoriai
US10022381B2 (en) 2008-05-23 2018-07-17 Pfizer Inc. Triazine compounds as PI3 kinase and mTOR inhibitors
ES2522346T3 (es) 2008-08-22 2014-11-14 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de CDK
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
MX338327B (es) 2010-10-25 2016-04-12 G1 Therapeutics Inc Inhibidores de cdk.
WO2013090829A1 (en) 2011-12-14 2013-06-20 Aragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
CA2868966C (en) 2012-03-29 2021-01-26 Francis Xavier Tavares Lactam kinase inhibitors
CA2915534A1 (en) 2013-06-19 2014-12-24 Seragon Pharmaceuticals, Inc. Azetidine estrogen receptor modulators and uses thereof
PE20170312A1 (es) 2014-03-14 2017-03-30 Pfizer Nanoparticulas terapeuticas que comprenden un agente terapeutico, y metodos para su elaboracion y uso
ES2881214T3 (es) 2014-12-17 2021-11-29 Pfizer Formulaciones de un inhibidor de PI3K/mTOR para la administración intravenosa
SI3672571T1 (sl) 2017-08-25 2022-01-31 Pfizer Inc. Farmacevtska vodna raztopina, ki vsebuje 1-(4-((4-(dimetilamino) piperdin-1-il)karbonil)fenil)-3-(4-(4,6-dimorfolin-4-il-1,3, 5-triazin-2-il)fenil)sečnino
EP4249069B1 (en) 2018-06-07 2025-11-19 Pfizer Inc. Aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
EP3863618A1 (en) * 2018-10-08 2021-08-18 F. Hoffmann-La Roche AG Methods of treating cancer with pi3k alpha inhibitors and metformin

Also Published As

Publication number Publication date
AU2025223785A1 (en) 2025-09-18
EP4376848A1 (en) 2024-06-05
AU2022320615B2 (en) 2025-08-21
US12350276B2 (en) 2025-07-08
TW202320795A (zh) 2023-06-01
US20230022525A1 (en) 2023-01-26
IL310243A (en) 2024-03-01
WO2023009438A1 (en) 2023-02-02
US20250345342A1 (en) 2025-11-13
CA3227191A1 (en) 2023-02-02
MX2024001266A (es) 2024-04-16
KR20240040768A (ko) 2024-03-28
AU2022320615A1 (en) 2024-03-14
CL2024000208A1 (es) 2024-07-19

Similar Documents

Publication Publication Date Title
JP6974669B2 (ja) Ｂ−Ｒａｆ阻害薬、ＥＧＦＲ阻害薬及び場合によってはＰＩ３Ｋ−α阻害薬を含む組合せ医薬
AU2017213541B2 (en) Combination therapy for the treatment of cancer
RU2737496C2 (ru) Способы лечения рака
JP2023175811A (ja) 類上皮細胞腫瘍を処置する方法
JP2021169457A (ja) ナノ粒子組成物のためのバイオマーカー
CN111032082B (zh) Her2阳性癌症的治疗
US20250345342A1 (en) Methods for the treatment of cancer using 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
US20260041695A1 (en) Combination therapies for treatment of breast cancer
CN102573477A (zh) 治疗方法
US20220241294A1 (en) Bisfluoroalkyl-1,4-benzodiazepinone compounds for treating notch-activated breast cancer
JP2020023497A (ja) 組合せ医薬
JP2022507686A (ja) 薬学的方法
CN117813097A (zh) 用于治疗癌症的1-(4-{[4-(二甲氨基)哌啶-1-基]羰基}苯基)-3-[4-(4,6-二吗啉-4-基-1,3,5-三嗪-2-基)苯基]脲（吉达利塞）及其组合
TWI843217B (zh) 一種藥物組合及其應用
US20250177414A1 (en) Combination therapies for treatment of breast cancer
WO2023059714A1 (en) Methods of treating estrogen receptor-mediated disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250715

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250715